Fig. 1
DEX expands M-MDSC after lung cancer surgery. A total of 103 lung cancer patients were divided into Ctrl (n = 51) and DEX (n = 52) group. The percentages of CD11b+CD33+HLA-DR− (MDSC), CD11b+CD33+HLA-DR−CD14− (G-MDSC) and CD11b+CD33+HLA-DR−CD14+ (M-MDSC) cells from peripheral blood mononuclear cells (PBMC) of lung cancer patients were analyzed by flow cytometry (FCM) at time of preoperatoin (T0), 1, 3 and 7 days after surgery (T1, T2 and T3). a Representative FCM data are shown. Frequency of (b) MDSC, c G-MDSC and d M-MDSC from PBMC of lung cancer patients during perioperative period